180 results
8-K
EX-99.1
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
%, as compared with Q1 2023. The decrease was related to the completion of a lease for a Bioservices customer at our Canton facility.
Contracts and Grants … revenue includes external customer sales, but does not include inter-segment services. The Company does not allocate contracts and grants, R&D, SG
8-K
EX-99.2
EBS
Emergent Biosolutions Inc
1 May 24
Emergent Biosolutions Reports First Quarter 2024 Financial Results
4:44pm
with U.S. government customer stakeholders Clarity gained on anthrax procurement levels New MCM contract awards and orders from the USG & DOD throughout … meets customer and patient needs Leading with integrity through a culture of quality and compliance across our enterprise. Addressed debt repayment
8-K
EX-99.1
EBS
Emergent Biosolutions Inc
6 Mar 24
Emergent Biosolutions Reports Fourth Quarter 2023 Financial Results
4:15pm
Spray 4 mg Over-The-Counter (“OTC NARCAN®”), broadening our customer base and sales channels to retail pharmacies and digital commerce websites as well … and segment adjusted gross margin, which is a non-GAAP financial measure. Segment revenue includes external customer sales, but does not include inter
8-K
EX-10.1
67mikf8eudbgr
21 Feb 24
Emergent BioSolutions Appoints Industry Leader Joseph C. Papa as New President and CEO
7:25am
8-K
EX-99.1
nfyb6koqp6 7mh
8 Nov 23
Emergent Biosolutions Reports Third Quarter 2023 Financial Results
4:21pm
8-K
EX-99.2
wt4a2bbv7kzkthue79
8 Nov 23
Emergent Biosolutions Reports Third Quarter 2023 Financial Results
4:21pm
8-K
EX-99.2
q8bncu7
8 Aug 23
Emergent Biosolutions Reports Financial Results for Second Quarter 2023
4:12pm
8-K
EX-99.1
hh66nih4x3cji
8 Aug 23
Emergent Biosolutions Reports Financial Results for Second Quarter 2023
4:12pm
8-K
EX-99.1
ef20g9bh gkwfvfls
8 Aug 23
Emergent BioSolutions Announces Strategic Steps to Strengthen Core Business and Financial Position
7:15am
424B5
pk3enqkpl p18
18 May 23
Prospectus supplement for primary offering
7:45am
8-K
EX-10.1
jgnhoxro5r 00zx9ck
17 May 23
Emergent’s Statement Regarding its Amended Credit Agreement
9:32pm
8-K
EX-99.2
w19r8 sen
9 May 23
Emergent Biosolutions Reports Financial Results for First Quarter 2023
4:05pm
8-K
EX-99.1
ulf 7vprivrx05v56u
9 May 23
Emergent Biosolutions Reports Financial Results for First Quarter 2023
4:05pm